Corbus Pharmaceuticals (CRBP) Corporate presentation summary

Strategic focus and pipeline

• Advancing novel oncology and obesity drugs with differentiated profiles targeting well-validated mechanisms and unmet needs.

• Pipeline includes CRB-701 (Nectin-4 ADC) for solid tumors and CRB-913 (CB1 inverse agonist) for obesity and related conditions.

• FDA Fast Track Designation granted for CRB-701 in HNSCC and cervical cancer.

• $138M in cash and equivalents as of March 31, 2026, with 17.7M shares outstanding.

CRB-701: Clinical profile and data

• Designed to reduce PADCEVⓇ-associated toxicities, extend half-life, and allow higher dosing.

• Demonstrates improved efficacy in tumors with high Nectin-4 expression, including HNSCC, cervical, and urothelial cancers.

• Lower levels of free MMAE and favorable safety profile compared to PADCEVⓇ.

• Phase 1/2 data show ORR of 47.6% in HNSCC and 37.5% in cervical cancer at 3.6 mg/kg dose.

• Peripheral neuropathy and skin adverse events are notably lower than competitors.

Market opportunities and competitive landscape

• Significant unmet need in 2L cervical cancer; current standard TivdakⓇ has modest efficacy (ORR 17.8%) and challenging tolerability.

• CRB-701 shows potential to displace TivdakⓇ with higher efficacy and better safety.

• Not pursuing mUC as a stand-alone indication due to market dominance by KeytrudaⓇ + PADCEVⓇ.